INCY · Q2 2025 Earnings

The dominant tonal shift this quarter is the arrival of new CEO Bill Meury and his explicit repositioning of Incyte from a company managing a 2029 patent cliff to one with — in his framing — a window to dominate MPNs. The framing language is unusually direct for this management team: "targeting driver mutations in MPNs is the holy grail...if you talk to a hematologist and ask, would you rather use a targeted monoclonal antibody versus a pathway approach, they'll select the target approach every time." That is not the language of a defensive portfolio; it's the language of a CEO staking the equity story on a single program (989) being category-redefining.

The 989 program itself has been re-rated internally based on the ET data readout. Management's posture has moved from measured optimism on the underlying biology to a confidence statement that mechanistic clarity in ET meaningfully raises the probability of success in MF. The verbatim: "when you have that mechanistic clarity in a set of patients, the probability that it will work on a different disease with the same molecular basis is certainly high." Translation: management wants investors to underwrite cross-indication readthrough rather than waiting for each data set in isolation.

Opzelura's framing also shifted from niche topical to secular growth franchise. Meury called it "a double digit kegger business, both US and of course internationally over the next several years, just with AD and with Vitiligo" — citing 20% topical-AD market growth and modest current penetration. The juxtaposition with the unchanged $630–670M FY guide is the tension: either management is sandbagging or they expect a 2H slowdown. Worth asking on the next call.

Risk language was not absent — management explicitly flagged the 2029 transition, R&D execution, Niktimvo launch volatility, and a "very high bar" for advancing the G12D solid-tumor program. But the framing puts those risks inside a value-creation narrative rather than a defensive one. Compared with prior Incyte communications, the call is markedly more forward-leaning.